Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?

absolute risk misclassification remaining lifetime risk risk threshold risk-stratified screening

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
15 Sep 2021
Historique:
received: 05 08 2021
revised: 03 09 2021
accepted: 13 09 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

In risk-stratified cancer screening, multiple risk factors are incorporated into the risk assessment. An individual's estimated absolute cancer risk is linked to risk categories with tailored screening recommendations for each risk category. Absolute risk, expressed as either remaining lifetime risk or shorter-term (five- or ten-year) risk, is estimated from the age at assessment. These risk estimates vary by age; however, some clinical guidelines (e.g., enhanced breast cancer surveillance guidelines) and ongoing personalised breast screening trials, stratify women based on absolute risk thresholds that do not vary by age. We examine an alternative approach in which the risk thresholds used for risk stratification vary by age and consider the implications of using age-independent risk thresholds on risk stratification. We demonstrate that using an age-independent remaining lifetime risk threshold approach could identify high-risk younger women but would miss high-risk older women, whereas an age-independent 5-year or 10-year absolute risk threshold could miss high-risk younger women and classify lower-risk older women as high risk. With risk misclassification, women with an equivalent risk level would be offered a different screening plan. To mitigate these problems, age-dependent absolute risk thresholds should be used to inform risk stratification.

Identifiants

pubmed: 34575693
pii: jpm11090916
doi: 10.3390/jpm11090916
pmc: PMC8469877
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Genome Canada
ID : 13529
Organisme : CIHR
ID : 155865
Pays : Canada

Références

Genet Med. 2019 Aug;21(8):1708-1718
pubmed: 30643217
J Natl Cancer Inst. 2015 May 08;107(7):
pubmed: 25956172
Stat Med. 2004 Apr 15;23(7):1111-30
pubmed: 15057881
Ann Intern Med. 2008 Mar 4;148(5):337-47
pubmed: 18316752
PLoS Med. 2019 Dec 20;16(12):e1002998
pubmed: 31860675
Nat Rev Clin Oncol. 2020 Nov;17(11):687-705
pubmed: 32555420
J Pers Med. 2021 Jun 04;11(6):
pubmed: 34199804
J Natl Cancer Inst. 1993 Jun 2;85(11):892-7
pubmed: 8492317
Int J Epidemiol. 2018 Apr 1;47(2):526-536
pubmed: 29315403
Breast Cancer Res. 2021 Feb 15;23(1):22
pubmed: 33588869
J Natl Cancer Inst. 2021 Apr 6;113(4):434-442
pubmed: 32853342
Curr Oncol. 2016 Dec;23(6):e615-e625
pubmed: 28050152
Nat Genet. 2002 May;31(1):33-6
pubmed: 11984562
JAMA Oncol. 2018 Nov 1;4(11):1504-1510
pubmed: 29978189
Nat Genet. 2013 Apr;45(4):400-5, 405e1-3
pubmed: 23455638
NPJ Breast Cancer. 2017 Sep 13;3:34
pubmed: 28944288

Auteurs

Nora Pashayan (N)

Department of Applied Health Research, University College London, London WC1E 7HB, UK.

Antonis C Antoniou (AC)

Centre for Cancer Genetic Epidemiology, Department of Public Health & Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge CB1 8RN, UK.

Andrew Lee (A)

Centre for Cancer Genetic Epidemiology, Department of Public Health & Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge CB1 8RN, UK.

Michael Wolfson (M)

School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.

Jocelyne Chiquette (J)

Department of Family Medicine and Emergency Medicine, Faculty of Medicine, Université Laval, Quebec City, QC G1V 4G2, Canada.
CHU de Québec-Université Laval Research Centre, Quebec City, QC G1S 4L8, Canada.

Laurence Eloy (L)

Quebec Cancer Program, Ministère de la Santé et des Services Sociaux, Quebec City, QC G1S 2M1, Canada.

Andrea Eisen (A)

Sunnybrook Health Science Centre, Toronto, ON M4N 3M5, Canada.

Tracy L Stockley (TL)

Division Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON M5G 2C4, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.

Hermann Nabi (H)

CHU de Québec-Université Laval Research Centre, Quebec City, QC G1S 4L8, Canada.
Department of Social and Preventive Medicine, Faculty of Medicine, Université Laval, Quebec City, QC G1V 0A6, Canada.

Jennifer D Brooks (JD)

Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.

Michel Dorval (M)

CHU de Québec-Université Laval Research Centre, Quebec City, QC G1S 4L8, Canada.
Faculty of Pharmacy, Université Laval, Quebec City, QC G1V 0A6, Canada.
CISSS de Chaudière-Appalaches Research Center, Lévis, QC G6V 3Z1, Canada.

Douglas F Easton (DF)

Centre for Cancer Genetic Epidemiology, Department of Public Health & Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge CB1 8RN, UK.

Bartha Maria Knoppers (BM)

Centre of Genomics and Policy, McGill University, Montreal, QC H3A 0G1, Canada.

Anna M Chiarelli (AM)

Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.
Ontario Health, Cancer Care Ontario, Toronto, ON M5G 2L3, Canada.

Jacques Simard (J)

CHU de Québec-Université Laval Research Centre, Quebec City, QC G1S 4L8, Canada.
Department of Molecular Medicine, Faculty of Medicine, Université Laval, Québec City, QC G1V 0A6, Canada.

Classifications MeSH